Drug intelligence / Profile preview

ConfometRx Target B program

Development stage: Preclinical
Lead developer: ConfometRx
Modality: Small Molecules
Administration: Oral, Subcutaneous, Intravenous, Intramuscular

Overview

ConfometRx Target B program is a preclinical drug discovery initiative focused on the development of small molecule modulators targeting an undisclosed G protein-coupled receptor (GPCR) for the treatment of metabolic diseases. Developed by ConfometRx, the program utilizes the company's proprietary structural biology platform to identify and optimize lead compounds. As of early 2024, the program is in the lead generation phase, aiming to identify potent and selective candidates for further development in metabolic indications.

Beyond the preview

Go deeper on ConfometRx Target B program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ConfometRx Target B program.

Explore the full profile